Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07224438
PHASE2

Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea

Sponsor: Stephanie B. Seminara, MD

View on ClinicalTrials.gov

Summary

The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.

Key Details

Gender

FEMALE

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-12-09

Completion Date

2030-05

Last Updated

2025-12-31

Healthy Volunteers

No

Interventions

DRUG

kisspeptin 112-121

SC administration of kisspeptin for two weeks (pulsatile, approximately every 90 minutes)

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States